The overall goal of this National Cooperative Drug Discovery Group (NCDDG) application is to design, synthesize and evaluate potential anticancer drugs based on inhibition of farnesylation of the ras oncogene product, mutated forms of which are involved in about 30% of human cancers. Farnesylation is required for Ras membrane association and malignant transformation. Therefore, the molecular target of our rational approach to cancer therapeutics is the enzyme Ras farensyltransferase (FTase), which catalyzes the transfer of a farnesyl isoprenoid lipid to the cysteine contained in the carboxylterminal CAAX sequence of Ras (C=cysteine, A=aliphatic, X=methionine or serine). We and others have designed CAAX peptidomimetics that block Ras farnesylation, signaling and transformation. Although these peptidomimetics are potent inhibitors of FTase in vitro, their ability to block Ras function in whole cells is weak and an intense search for better inhibitors is underway. A better understanding of the inhibitors structure activity relationship with FTase, their mechanism of action and the basis of their selectivity at the biochemical, the cellular signaling and the in vivo level will be critical to the successful design of clinically useful FTase inhibitors. Our multidisciplinary approach to accomplish these goals consists of three distinct but complementary programs. Program #1 will design and synthesize CAAX peptidomimetics, transition state bisubstrate analogs of the farnesylpyrophosphate/CAAX complex and mechanism-based inhibitors. Using a variety of substrates, Program #2 will perform structure/function studies on these compounds to determine the requirements for selective inhibition of farnesylation relative to geranylgeranylation in vitro and in vivo and the effects of the compounds on cell growth. Program #3 will determine the effects of these compounds on Ras signaling and transformation in cell culture systems. Both Programs #2 and #3 will address selectivity issues in terms of, H-vs. K-vs. N-Ras, Ras vs. Ras- related proteins, and Ras vs. other oncogene products. Feedback from Programs #2 and #3 will be used by Program #1 to produce second and third generation leads. The best lead compounds to emerge from these combined studies will then be evaluated by Program #2 for their ability to specifically block the growth of tumors with aberrant Ras function, using a nude mouse xenograft model. Finally, advanced preclinical and clinical studies will be carried out in collaboration with our industrial and clinical partners. The work described in this NCDDG will enhance our understanding of the mechanism of action of Ras FTase inhibitors, and ultimately result in novel anticancer drugs that will broaden the spectrum of human tumors that can be treated successfully.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA067771-03
Application #
2517631
Study Section
Special Emphasis Panel (SRC (08))
Project Start
1996-09-20
Project End
1998-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of South Florida
Department
Biochemistry
Type
Schools of Medicine
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Patel, R A; Liu, Y; Wang, B et al. (2014) Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 33:550-5
Vigil, Dominico; Kim, Tai Young; Plachco, Ana et al. (2012) ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res 72:5338-47
Li, Rongshi; Martin, Mathew P; Liu, Yan et al. (2012) Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem 55:2474-8
Pireddu, Roberta; Forinash, Kara D; Sun, Nan N et al. (2012) Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm 3:699-709
Mitin, Natalia; Roberts, Patrick J; Chenette, Emily J et al. (2012) Posttranslational lipid modification of Rho family small GTPases. Methods Mol Biol 827:87-95
Patel, Ronil A; Forinash, Kara D; Pireddu, Roberta et al. (2012) RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res 72:5025-34
Berndt, Norbert; Hamilton, Andrew D; Sebti, Saïd M (2011) Targeting protein prenylation for cancer therapy. Nat Rev Cancer 11:775-91
Xu, Dapeng; Allsop, Stephen A; Witherspoon, Sam M et al. (2011) The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis 32:488-95
Baines, Antonio T; Xu, Dapeng; Der, Channing J (2011) Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 3:1787-808
Martin, Timothy D; Samuel, Jonathan C; Routh, Elizabeth D et al. (2011) Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res 71:206-15

Showing the most recent 10 out of 117 publications